Skip to content

Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behaviors in Autism

Repetetive Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behavior in Subjects With Autism Spectrum Disorders.

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01983189
Enrollment
10
Registered
2013-11-13
Start date
2008-11-30
Completion date
2010-11-30
Last updated
2017-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asperger Disorder, Autism, Other Developmental Pervasive Disorder

Keywords

TMS, transcranial magnetic stimulation, rTMS, recurrent transcranial magnetic stimulation, fMRI, functional magnetic resonance imaging.

Brief summary

This study is a trial of low frequency Repetitive Transcranial magnetic stimulation( rTMS) for subjects with autism spectrum disorders, specially targeting repetitive behaviors.

Detailed description

This project is a 3-week double blind cross-over trial for adolescents and adults who meet criteria for autism and have clinically prominent repetitive behaviors. The investigator will apply low frequency rTMS for 20 minutes 5 times a week for 3 weeks targeting the area of brain which was involved in repetitive behaviors. The investigator will obtain clinical measures of repetitive behaviors as well as social functioning pre and post treatment. As a control and a cross-over condition , we will stimulate other area of brain which has nothing to do with repetitive behaviors but may improve social functioning in autism spectrum disorders. In addition to r TMS we will perform a pre and post treatment perfusion functional MRI and obtain TMS measure of excitability of brain.

Interventions

PROCEDUREtranscranial magnetic stimulation

1 hz transcranial magnetic stimulation

Sponsors

New York State Psychiatric Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

1. English Speaking 2. Capacity to give consent and sign HIPAA Authorization 3. Patients currently taking psychotropic medications must be at the same stable dose and likely to be able to continue at the same dose throughout the study 4. ASD diagnosis according to the DSM-IV TR Symptom and Criterion checklist for ASD 5. Significant level of repetitive behaviors to distinguish from movement disorders to be in at least 3 out of 6 sub-scales (stereotyped behavior, self-injurious behavior, compulsive behavior, ritualistic behavior, sameness behavior, restricted behavior) -

Exclusion criteria

1. Women of child-bearing potential not using birth control, pregnant or breast feeding 2. H/o Bipolar Disorder (lifetime), any Psychotic Disorder (lifetime) history of Major Depressive Disorder or of substance abuse or dependence within the past year 3. Significant sub-average intellectual function (IQ\<70) 4. Intracranial implants 5. Increased risk of seizure for any reason, including prior diagnosis of epilepsy, seizure disorder, febrile seizure, increased intracranial pressure or history of significant head trauma with loss of consciousness for \> 5 minutes. 6. Current significant laboratory abnormality 7. Neurological disorder including but not limited to space occupying brain lesion, any history of seizures, history of cerebrovascular accident, fainting, cerebral aneurysm, dementia, Huntington chorea, Multiple Sclerosis -

Design outcomes

Primary

MeasureTime frame
clinical improvement based on repetitive behavior scale.baseline-week3

Secondary

MeasureTime frame
clinical improvement based on the social responsiveness scale.before-week3

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026